Medical management of adrenal disease: A narrative review

Endocrine Regulations

Volumn 43, Issue 3, 2009, Pages 127-135

  Michalakis, K ^a   Ilias, I ^a  

^a E Venizelou Hospital   (Greece)

Author keywords

Adrenal cancer; Adrenal gland; Adrenal insufficiency; Adrenocortical hyperfunction; Congential adrenal hyperplasia; Cushing's syndrome; Drug therapy; Hyperaldosteronism; Pheochromocytoma

Indexed keywords

AMINOGLUTETHIMIDE; ATENOLOL; BROMOCRIPTINE; CARBENOXOLONE; DEXAMETHASONE; DOXAZOSIN; ETOMIDATE; FLUDROCORTISONE; FLUTAMIDE; HYDROCORTISONE; KETANSERIN; KETOCONAZOLE; LABETALOL; METERGOLINE; METOPROLOL; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PHENOXYBENZAMINE; PRAZOSIN; PREDNISONE; PROPRANOLOL; RITANSERIN; SOMATOSTATIN; TERAZOSIN; TESTOLACTONE; TRILOSTANE; UNINDEXED DRUG; VALPROIC ACID;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ADRENAL DISEASE; ADRENAL INSUFFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLURRED VISION; CANCER SURGERY; CONFUSION; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DEPRESSION; DIARRHEA; DIZZINESS; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPERALDOSTERONISM; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; LIVER DISEASE; NAUSEA; PHEOCHROMOCYTOMA; SEDATION; SIDE EFFECT; STEROID 21 MONOOXYGENASE DEFICIENCY; SURGICAL TECHNIQUE; TERATOGENICITY; VERTIGO; ADRENAL GLAND; ADRENAL TUMOR; CLINICAL TRIAL; REVIEW;

ADRENAL GLAND DISEASES; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADRENAL HYPERPLASIA, CONGENITAL; ADRENAL INSUFFICIENCY; ADRENOCORTICAL CARCINOMA; CLINICAL TRIALS AS TOPIC; CUSHING SYNDROME; HUMANS; HYPERALDOSTERONISM; PHEOCHROMOCYTOMA;

EID: 70350718245     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2009_03_127     Document Type: Article

References (51)

1. Arlt W: Androgen therapy in women. Eur J Endocrinol 154,1-11, 2006. doi:10.1530/eje.1.02062
2. Arlt W, Krone N: Adult consequences of congenital adrenal hyperplasia. Horm Res 68, 158-164, 2007. doi:10.1159/000110615
3. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB et al.: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88, 5593-5602, 2003. doi:10.1210/jc.2003-030871
4. Bertherat J, Coste J, Bertagna X, Dickstein G, Shechner C, Nativ O, Lee JE, Machens A, Dralle H, Terzolo M et al.: Adjuvant Mitotane in Adrenocortical Carcinoma. N Engl J Med 357, 1256-1259, 2007. doi:10.1056/NEJMc076267
5. Biglieri EG, Kater CE: Mineralocorticoids in congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 40, 493-499, 1991. doi:10.1016/0960-0760(91)90268-A
6. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86, 5658-5671, 2001. doi:10.1210/jc.86.12.5658
7. Browers FM, Lenders JW, Eisenhofer G, Pacak K: Phaeochromocytoma as an endocrine emergency. Rev Endocrinol Metab Disord 4, 121-128, 2003. doi:10.1023/A:1022981801344
8. Calhoun DA: Aldosteronism and hypertension. Clin J Am Soc Nephrol 1, 1039-1045, 2006. doi:10.2215/CJN.01060306
9. Clayton PE, Miller WL, Oberfield SE, Ritzén EM, Sippell WG, Speiser PW,Group ELCW: Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 58, 188-195, 2002. doi:10.1159/000065490
10. Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348, 727-734, 2003. doi:10.1056/NEJMra020529
11. Dewis P, Anderson DC, Bulock DE, Earnshaw R, Kelly WF: Experience with trilostane in the treatment of Cushing's syndrome. Clin Endocrinol 18, 533-540, 1983. doi:10.1111/j.1365-2265.1983.tb00590.x
12. Diez JJ, Iglesias P: Pharmacological therapy of Cushing's syndrome: drugs and indications. Mini Rev Med Chem 7, 467-480, 2007. doi:10.2174/138955707780619653
13. Gotoh H, Kusakabe M, Shiroishi T, Moriwaki K: Survival of steroid 21-hydroxylase-deficient mice without endogenous corticosteroids after neonatal treatment and genetic rescue by transgenesis as a model system for treatment of congenital adrenal hyperplasia in humans. Endocrinology 135, 1470-1476, 1994. doi:10.1210/en.135.4.1470
14. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A: Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 24, 532-535, 2001
15. Janmohamed S, Bouloux PM: The pharmacological treatment of primary aldosteronism. Expert Opin Pharmacother 7, 563-573, 2006. doi:10.1517/14656566.7.5.563
16. Kageyama Y, Kitahara S, Tsukamoto T, Tsujii T, Goto S, Oshima H: Chlormadinone acetate as a possible effective agent for congenital adrenal hyperplasia to suppress elevated ACTH and antagonize masculinization. Endocr J 42, 505-508, 1995. doi:10.1507/endocrj.42.505
17. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK: Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 86, 4104-4108, 2001. doi:10.1210/jc.86.9.4104
18. Lebuffe G, Dosseh ED, Tek G, Tytgat H, Moreno S, Tavernier B, Vallet B, Proye CA: The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 60, 439-444, 2005. doi:10.1111/j.1365-2044.2005.04156.x
19. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322, 1195-1201, 1990
20. Manelli M: Management and Treatment of Pheochromocytomas and Paragangliomas. Ann NY Acad Sci 1073, 405-416, 2006. doi:10.1196/annals.1353.044
21. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR: The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25, 309-340, 2004. doi:10.1210/er.2002-0031
22. Mantero F, Matarello MJ, Albiger NM: Detecting and treating primary aldosteronism. Exp Clin Endocrinol Diabetes 115, 171-174 2007. doi:10.1055/s-2007-970409
23. Merke DP: Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab 93, 653-660, 2008. doi:10.1210/jc.2007-2417
24. Merke DP, Bornstein SR: Congenital adrenal hyperplasia. Lancet 365, 2125-2136, 2005. doi:10.1016/S0140-6736(05)66736-0
25. Mieure KD, Smith KM, Winstead PS: Supplemental glucocorticoid therapy. Orthopedics 30, 116-119, 2007
26. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS: The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in ageadvanced men and women. Clin Endocrinol 49, 421-432, 1998. doi:10.1046/j.1365-2265.1998.00507.x
27. Munver R, Volfson IA: Adrenal insufficiency: diagnosis and management. Curr Urol Rep 7, 80-85, 2006. doi:10.1007/s11934-006-0046-5.
28. Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing's syndrome. Lancet 36, 1605-1617, 2006. doi:10.1016/S0140-6736(06)68699-6
29. Nieman LK: Medical therapy of Cushing's disease. Pituitary 5, 77-82, 2002. doi:10.1023/A:1022308429992
30. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL: Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61, 536-540, 1985
31. Nieman LK, Ilias I: Evaluation and treatment of Cushing's syndrome. Am J Med 118, 1340-1346, 2005. doi:10.1016/j.amjmed.2005.01.059
32. Nimkarn S, New MI: Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Mol Cell Endocrinol 300, 192-196, 2009. doi:10.1016/j.mce.2008.11.027
33. Norton JA: Adrenal tumors. In: V. T. De Vita, Jr., S. Hellman, et al (Ed.). Cancer:principles and practice of oncology. Philadelphia, PA: Lippincot Williams & Wilkins, 2005. Adrenal tumors, p.1528-1539
34. Pacak K: Preoperative management of the phaeochromocytoma patient. J Clin Endocrinol Metab 92, 4069-4079, 2007.doi:10.1210/jc.2007-1720
35. Padfield PL: Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol 59, 422-426, 2003. doi:10.1046/j.1365-2265.2003.01817.x
36. Pederson LC, Lee JE: Phaeochromocytoma. Curr Treat Options Oncol 4, 329-337, 2003. doi:10.1007/s11864-003-0008-9
37. Pimenta E, Calhoun DA: Primary aldosteronism:diagnosis and treatment. J Clin Hypertens 8, 887-893, 2006. doi:10.1111/j.1524-6175.2006.06107.x
38. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B, Fassnacht M: Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; doi:10.1210/jc.2007-2564. doi:10.1210/jc.2007-2564
39. Ross RJ, Rostami-Hodjegan A: Timing and type of glucocorticoid replacement in adult congenital adrenal hyperplasia. Horm Res 64, 67-70, 2005. doi:10.1159/000087757
40. Schulick RD Brennan MF: Adrenocortical carcinoma. In: A. Belldegrum, A. Ritchie, et al (Ed.). Renal and adrenal tumors: Biology and management. Oxford: Oxford University Press, 2003. Adrenocortical carcinoma, p.543-549
41. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B: Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70, 1426-1430, 1990
42. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 358, 111-124, 2008. doi:10.1056/NEJMoa071366
43. Steinsapir J, Carr AA, Prisant LM, Bransome ED, Jr.: Metyrosine and phaeochromocytoma. Arch Intern Med 157, 901-906, 1997. doi:10.1001/archinte.157.8.901
44. van der Horst-Schrivers ANA, Kerstens MN, Wolffenbuttel BHR: Preoperative pharmacological management of phaeochromocytoma. Nether J Med 64, 290-295, 2006
45. Van Wyk JJ, Gunther DF, Ritzen EM, Wedell A, Cutler GB, Jr., Migeon CJ, New MI: The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab 81, 3180-3190, 1996. doi:10.1210/jc.81.9.3180
46. Vaughan ED, Jr.: Diseases of the adrenal gland. Med Clin N Am 88, 443-466, 2004. doi:10.1016/S0025-7125(03)00149-4
47. White PC, Speiser PW: Long-term consequences of childhood-onset congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 16, 273-288, 2002. doi:10.1053/beem.2002.0198
48. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21 hydroxylase deficiency Endocrine Reviews 21, 245-291, 2000. doi:10.1210/er.21.3.245
49. Young W, Jr.: Primary aldosteronism-Changing concepts in diagnosis and treatment. Endocrinology 144, 2208-2213, 2003a. doi:10.1210/en.2003-0279
50. Young WF, Jr.: Primary aldosteronism-treatment options. Growth Horm IGF Res 13, S102-S108, 2003b. doi:10.1016/S1096-6374(03)00064-9
51. Young WF, Jr.: Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 66, 607-618, 2007. doi:10.1111/j.1365-2265.2007.02775.x.